RESUMO
BACKGROUND: Deferriferrichrysin (Dfcy) is a siderophore found in foods fermented by Aspergillus oryzae and is a promising candidate for an antioxidant food additive because of its high binding constant toward iron. However, the Dfcy concentration is typically low in foods and cultures. RESULTS: We optimised culture conditions to improve Dfcy production to 2800 mg L(-1) from 22.5 mg L(-1) under typical conditions. Then, we evaluated the potential of Dfcy as a food additive by measuring its safety, stability, and antioxidant activity. Dfcy was sufficiently stable that over 90% remained after pasteurisation at 63 °C for 30 min at pH 3-11, or after sterilisation at 120 °C for 4 min at pH 4-6. Dfcy showed high antioxidant activity in an oil-in-water model, where inhibition of lipid oxidation was measured by peroxide value (PV) and thiobarbituric acid reactive substances (TBARS) assays. Dfcy decreased PV and TBARS by 83% and 75%, respectively. Antioxidant activity of Dfcy was equal to or higher than that of the synthetic chelator EDTA. CONCLUSION: Our study provides the first practical method for production of Dfcy. Dfcy can be a novel food-grade antioxidant and the first natural alternative to the synthesised iron chelator EDTA. © 2015 Society of Chemical Industry.
Assuntos
Antioxidantes/isolamento & purificação , Aspergillus oryzae/química , Conservantes de Alimentos/isolamento & purificação , Quelantes de Ferro/isolamento & purificação , Modelos Químicos , Peptídeo Hidrolases/metabolismo , Peptídeos Cíclicos/isolamento & purificação , Animais , Antioxidantes/efeitos adversos , Antioxidantes/química , Antioxidantes/economia , Aspergillus oryzae/crescimento & desenvolvimento , Aspergillus oryzae/metabolismo , Fermentação , Conservantes de Alimentos/efeitos adversos , Conservantes de Alimentos/química , Conservantes de Alimentos/economia , Indústria de Processamento de Alimentos/economia , Proteínas Fúngicas/metabolismo , Temperatura Alta/efeitos adversos , Resíduos Industriais/análise , Resíduos Industriais/economia , Quelantes de Ferro/efeitos adversos , Quelantes de Ferro/química , Quelantes de Ferro/economia , Japão , Testes de Mutagenicidade , Oryza/química , Peptídeos Cíclicos/efeitos adversos , Peptídeos Cíclicos/química , Peptídeos Cíclicos/economia , Proteínas de Vegetais Comestíveis/química , Proteínas de Vegetais Comestíveis/economia , Proteínas de Vegetais Comestíveis/isolamento & purificação , Proteínas de Vegetais Comestíveis/metabolismo , Hidrolisados de Proteína/química , Hidrolisados de Proteína/economia , Hidrolisados de Proteína/isolamento & purificação , Hidrolisados de Proteína/metabolismo , Saccharomyces cerevisiae/crescimento & desenvolvimento , Saccharomyces cerevisiae/metabolismo , Sementes/química , Testes de Toxicidade Aguda , Vinho/análise , Vinho/microbiologiaRESUMO
Threats to the status of clinical research have been well documented in the past three decades, and the National Institutes of Health and the Congress have done much to alleviate them. But the relationships of academic investigators and pharmaceutical companies remain a treacherous area. This vital nexus, on which so much progress depends, must be carefully maintained. In this paper I present two examples of academic/pharmaceutical company collaborations, both in search of a similar drug. The cases illustrate both some important hazards and accomplishments of clinical research.